Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults
성인에서 RBD-이량체 기반 코비드-19 백신 ZF2001의 효능 및 안전성
Clinical Trial
Published on
Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단,
Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단,
[키워드] 1:1
95% CI
95% confidence interval
acute respiratory syndrome
Adults
adverse event
Adverse reaction
age
aluminum
Analysis
assigned
China
Clinical Center
clinical trials
conducted
coronavirus
coronavirus disease
Cutoff
death
deaths
dimeric
dose
double-blind
effective
Efficacy
efficacy analysis
efficacy end point
Follow-up
hydroxide
immunogenic
incidence
Indonesia
large cohort
Major
MOST
occurred
Occurrence
participant
Participants
phase 3 trial
Placebo
placebo-controlled
primary end point
primary end-point
Randomized
Randomly
receive
regimen
reported
Safe
Safety
safety analysis
Science
Serious Adverse Event
shown
Side-effect
symptomatic
technology
the placebo group
the receptor-binding domain
Trial
two groups
vaccination
Vaccine
was performed
ZF2001
[DOI] 10.1056/NEJMoa2202261 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2202261 PMC 바로가기 [Article Type] Clinical Trial